Merck & Company (MRK)

$99.72 -1.17 (-1.16%)
Market Cap 250.41B
Revenue (ttm) 64.17B
Net Income (ttm) 17.12B
EPS (ttm) N/A
PE Ratio 11.82
Forward PE 11.38
Profit Margin 26.68%
Debt to Equity Ratio 0.77
Volume 16,430,388
Avg Vol 13,350,834
Day's Range N/A - N/A
Shares Out 2.48B
Stochastic %K 9%
Beta 0.29
Analysts Strong Sell
Price Target $106.69

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
AStrokeOfLuck
AStrokeOfLuck Dec. 6 at 1:50 AM
$MRK $GSK $SPY $DVAX
1 · Reply
bavariaron
bavariaron Dec. 6 at 1:33 AM
$VKTX ** Insight: Quiet Period is a Fantasy ** Bidding wars public and behind the scenes for mid to late stage biotechs. @Seedy19Tron on X about MRK—CDTX Acquisition: “You guys are gonna mute me at this rate , but so many takeaways. $CDTX literally had their earnings call on 11/07!!! I think gone are the days of ‘quiet period’ and CEOs dropping out of conferences.” $CDTX $MRK mergers details out 10/24 -$118 offer from company D 10/29- $120 offer from $MRK 11/01 - $130 offer from company D 11/04 - $104 offer from company E 11/07 - $150 offer from company D 11/08 - $156 offer from $MRK 11/08 - $140 offer from company F 11/08 - $127 + cvr offer from company E 11/11 - $158 offer from company E 11/11 - $165 offer from company F 11/13 - $173.5 offer from company E 11/13 - $185 offer from company F 11/13 - $221.5 offer from $MRK accepted 11/14 - announcement VKTX Absolutely
3 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:22 AM
Actionable Trade Alert for $MRK: Market Context: $MRK is currently trading at $100.89, showing strength as it approaches the 60-day high of $105.84. The RSI of 66.98 indicates that the stock is nearing overbought territory, suggesting caution but also potential for upward momentum. Directional Bias: With the current price above the MA30 (92.83) and MA50 (89.87), the trend appears bullish. The proximity to the 60D high reinforces a positive outlook, but the RSI indicates a potential pullback may occur. Trade Plan: - Suggested Entry: $100.89 - Stop Loss: $97.74 (approximately 3% below entry) - Take Profit Targets: 1. $104.00 (3.1% gain) 2. $107.00 (6.5% gain) 3. $118.00 (17.0% gain) This plan allows for a favorable risk-reward ratio while targeting significant upside. Monitor the price action closely, especially around the high. https://privateprofiteers.com
0 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 11:36 PM
$MRK $GILD IMHO, even just a small slice in regards to licensing fees for $CDXS would have a HUGE impact on the company going forward. "Pifeltro-islatravir will reach blockbuster status by 2030, with the combination estimated to pull in $1.7BN by 2033, as per a patient-based forecast from analysts at GlobalData. However, islatravir could have another shot at glory on the HIV market, as two Phase III trials are currently assessing islatravir plus Gilead’s HIV drug, Sunlenca (lenacapavir). The combination was recently found to maintain viral suppression for two years when administered orally once-weekly in a Phase II trial." https://www.clinicaltrialsarena.com/news/msd-merck-hiv-doravirine-islatravir-phase-iii/?cf-view
0 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 11:21 PM
$CDXS $MRK https://newdrugapprovals.org/2020/02/13/islatravir-mk-8591-efda/
1 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 11:13 PM
$CDXS $MRK https://www.fiercebiotech.com/biotech/mercks-hiv-combo-matches-gileads-biktarvy-phase-3-test
0 · Reply
TwongStocks
TwongStocks Dec. 5 at 10:16 PM
$CDTX Tender offer filed with the SEC https://www.sec.gov/Archives/edgar/data/310158/000119312525309877/d78449dsctot.htm • $MRK tender offer is $221.50 for each common share of CDTX and $15,505 for each Series A preferred share. • Tender offer expires one minute following 11:59 p.m., Eastern Time, on January 6, 2026, unless extended or earlier terminated.
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 8:35 PM
$SMX need a #shortsqueeze at $JANX👀🤑 News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 8:34 PM
$TGL need a #shortsqueeze at $JANX 👀🤑 News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 8:34 PM
$WHLR need a #shortsqueeze at $JANX 👀🤑 News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
Latest News on MRK
Do These 3 Healthcare Stocks Need a Checkup?

Dec 5, 2025, 4:05 PM EST - 13 hours ago

Do These 3 Healthcare Stocks Need a Checkup?

BMY PFE

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Dec 5, 2025, 1:35 PM EST - 15 hours ago

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

GSK SNY

Is This Pharmaceutical Giant a Buy After a Major Acquisition?

Dec 5, 2025, 12:05 PM EST - 17 hours ago

Is This Pharmaceutical Giant a Buy After a Major Acquisition?

These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?

Dec 5, 2025, 3:15 AM EST - 1 day ago

These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?

ALB SOLV

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Dec 4, 2025, 1:53 PM EST - 1 day ago

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

PLRX

FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

Dec 4, 2025, 12:05 PM EST - 1 day ago

FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 6:03 PM EST - 2 days ago

Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 4:13 AM EST - 3 days ago

Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript

17 dividend-stock bargains from a value manager with a stellar track record

Dec 2, 2025, 12:11 PM EST - 3 days ago

17 dividend-stock bargains from a value manager with a stellar track record

BMY CIVI CMCSA CVS MOS MTH OMC

Top 10 High-Yield Dividend Stocks For December 2025

Dec 1, 2025, 2:20 PM EST - 4 days ago

Top 10 High-Yield Dividend Stocks For December 2025

ACN ADP CMCSA EOG NEE NKE PAG

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

Dec 1, 2025, 6:45 AM EST - 4 days ago

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders

Nov 30, 2025, 4:45 AM EST - 6 days ago

These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders

BNS ENB

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?

Nov 29, 2025, 6:33 PM EST - 6 days ago

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?

Merck: Excellence Across The Board

Nov 28, 2025, 10:00 AM EST - 7 days ago

Merck: Excellence Across The Board

Why Is Merck Stock Surging?

Nov 26, 2025, 8:25 AM EST - 9 days ago

Why Is Merck Stock Surging?

Merck to Participate in the Citi 2025 Global Healthcare Conference

Nov 26, 2025, 7:15 AM EST - 9 days ago

Merck to Participate in the Citi 2025 Global Healthcare Conference

Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference

Nov 26, 2025, 6:45 AM EST - 9 days ago

Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches

Nov 24, 2025, 6:45 AM EST - 11 days ago

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches

Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks

Nov 23, 2025, 3:45 PM EST - 12 days ago

Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks

CLS COMM MU OMF PINE

Merck Recommends Rejection of Tutanota's “Mini-Tender” Offer

Nov 21, 2025, 7:30 PM EST - 14 days ago

Merck Recommends Rejection of Tutanota's “Mini-Tender” Offer

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Nov 21, 2025, 4:12 PM EST - 14 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Retirement: 2 Healthcare Giants To Buy At Discounted Prices

Nov 21, 2025, 8:00 AM EST - 14 days ago

Retirement: 2 Healthcare Giants To Buy At Discounted Prices

ELV

Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 12:13 PM EST - 15 days ago

Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 15 days ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY GILD IVV PFE SPY VOO

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?

Nov 20, 2025, 9:45 AM EST - 15 days ago

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Nov 19, 2025, 1:23 PM EST - 16 days ago

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

Nov 19, 2025, 1:05 PM EST - 16 days ago

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

CDTX

Merck's oral HIV treatment meets main goal in late-stage study

Nov 19, 2025, 6:50 AM EST - 16 days ago

Merck's oral HIV treatment meets main goal in late-stage study

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

Nov 19, 2025, 6:45 AM EST - 16 days ago

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

Nov 19, 2025, 6:30 AM EST - 16 days ago

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 17 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT NVO OLMA PFE

Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

Nov 18, 2025, 12:42 PM EST - 17 days ago

Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

Merck Announces First-Quarter 2026 Dividend

Nov 18, 2025, 11:30 AM EST - 17 days ago

Merck Announces First-Quarter 2026 Dividend

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 17 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK JNJ

Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Nov 18, 2025, 6:45 AM EST - 17 days ago

Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Merck Has Many Bullish Attributes (Technical Analysis)

Nov 18, 2025, 4:18 AM EST - 18 days ago

Merck Has Many Bullish Attributes (Technical Analysis)

Merck & Co., Inc. (MRK) M&A Call Transcript

Nov 17, 2025, 10:27 AM EST - 18 days ago

Merck & Co., Inc. (MRK) M&A Call Transcript

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

Nov 17, 2025, 8:34 AM EST - 18 days ago

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

CDTX

Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November

Nov 17, 2025, 4:31 AM EST - 19 days ago

Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November

RGLD

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Nov 16, 2025, 6:49 PM EST - 19 days ago

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

CDTX

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Nov 14, 2025, 6:17 PM EST - 21 days ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

CDTX IBB XBI XLV

Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 5:01 PM EST - 21 days ago

Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 21 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN JNJ LLY NVO PFE XLV

Merck Is Paying Up for Flu Biotech as M&A Spree Continues

Nov 14, 2025, 11:30 AM EST - 21 days ago

Merck Is Paying Up for Flu Biotech as M&A Spree Continues

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

Nov 14, 2025, 11:20 AM EST - 21 days ago

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

CDTX

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

Nov 14, 2025, 10:00 AM EST - 21 days ago

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

NVDA CDTX STUB

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

Nov 14, 2025, 8:30 AM EST - 21 days ago

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

CDTX

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Nov 14, 2025, 7:16 AM EST - 21 days ago

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

CDTX

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

Nov 14, 2025, 6:51 AM EST - 21 days ago

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

CDTX

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

Nov 14, 2025, 6:45 AM EST - 21 days ago

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

CDTX

AStrokeOfLuck
AStrokeOfLuck Dec. 6 at 1:50 AM
$MRK $GSK $SPY $DVAX
1 · Reply
bavariaron
bavariaron Dec. 6 at 1:33 AM
$VKTX ** Insight: Quiet Period is a Fantasy ** Bidding wars public and behind the scenes for mid to late stage biotechs. @Seedy19Tron on X about MRK—CDTX Acquisition: “You guys are gonna mute me at this rate , but so many takeaways. $CDTX literally had their earnings call on 11/07!!! I think gone are the days of ‘quiet period’ and CEOs dropping out of conferences.” $CDTX $MRK mergers details out 10/24 -$118 offer from company D 10/29- $120 offer from $MRK 11/01 - $130 offer from company D 11/04 - $104 offer from company E 11/07 - $150 offer from company D 11/08 - $156 offer from $MRK 11/08 - $140 offer from company F 11/08 - $127 + cvr offer from company E 11/11 - $158 offer from company E 11/11 - $165 offer from company F 11/13 - $173.5 offer from company E 11/13 - $185 offer from company F 11/13 - $221.5 offer from $MRK accepted 11/14 - announcement VKTX Absolutely
3 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:22 AM
Actionable Trade Alert for $MRK: Market Context: $MRK is currently trading at $100.89, showing strength as it approaches the 60-day high of $105.84. The RSI of 66.98 indicates that the stock is nearing overbought territory, suggesting caution but also potential for upward momentum. Directional Bias: With the current price above the MA30 (92.83) and MA50 (89.87), the trend appears bullish. The proximity to the 60D high reinforces a positive outlook, but the RSI indicates a potential pullback may occur. Trade Plan: - Suggested Entry: $100.89 - Stop Loss: $97.74 (approximately 3% below entry) - Take Profit Targets: 1. $104.00 (3.1% gain) 2. $107.00 (6.5% gain) 3. $118.00 (17.0% gain) This plan allows for a favorable risk-reward ratio while targeting significant upside. Monitor the price action closely, especially around the high. https://privateprofiteers.com
0 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 11:36 PM
$MRK $GILD IMHO, even just a small slice in regards to licensing fees for $CDXS would have a HUGE impact on the company going forward. "Pifeltro-islatravir will reach blockbuster status by 2030, with the combination estimated to pull in $1.7BN by 2033, as per a patient-based forecast from analysts at GlobalData. However, islatravir could have another shot at glory on the HIV market, as two Phase III trials are currently assessing islatravir plus Gilead’s HIV drug, Sunlenca (lenacapavir). The combination was recently found to maintain viral suppression for two years when administered orally once-weekly in a Phase II trial." https://www.clinicaltrialsarena.com/news/msd-merck-hiv-doravirine-islatravir-phase-iii/?cf-view
0 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 11:21 PM
$CDXS $MRK https://newdrugapprovals.org/2020/02/13/islatravir-mk-8591-efda/
1 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 11:13 PM
$CDXS $MRK https://www.fiercebiotech.com/biotech/mercks-hiv-combo-matches-gileads-biktarvy-phase-3-test
0 · Reply
TwongStocks
TwongStocks Dec. 5 at 10:16 PM
$CDTX Tender offer filed with the SEC https://www.sec.gov/Archives/edgar/data/310158/000119312525309877/d78449dsctot.htm • $MRK tender offer is $221.50 for each common share of CDTX and $15,505 for each Series A preferred share. • Tender offer expires one minute following 11:59 p.m., Eastern Time, on January 6, 2026, unless extended or earlier terminated.
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 8:35 PM
$SMX need a #shortsqueeze at $JANX👀🤑 News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 8:34 PM
$TGL need a #shortsqueeze at $JANX 👀🤑 News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 8:34 PM
$WHLR need a #shortsqueeze at $JANX 👀🤑 News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:52 PM
$TGL need a #shortsqueeze at $JANX News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. $JANX Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:51 PM
$CAPR need a #shortsqueeze at $JANX News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. $JANX Professor GPT agrees -
2 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:48 PM
$NVO need a #shortsqueeze at $JANX Beyond oversold. News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:46 PM
$WHLR need a #shortsqueeze at $JANX News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:44 PM
$SMX need a #shortsqueeze at $JANX News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out. Stock currently trading BELOW Net Cash - insane. Easy money for those who jump in now. Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:42 PM
$TGL need a #shortsqueeze at $JANX News of JANX008 coming any day now (scheduled for Q4 release) along with increasing rumors of a $MRK buy out Professor GPT agrees -
0 · Reply
RainMan_17
RainMan_17 Dec. 5 at 7:26 PM
$JANX $MRK
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 5 at 5:46 PM
Enter: $MRK Calls Strike Price: $101 Expiry Date: DEC 26 2025 Buy in Price: $2.00 - $2.65 Sell Price: $3.79 Profit : +43% (Turn every $1 into $1.43) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 5:29 PM
$CDXS $JNJ $PFE $MRK This is pretty interesting! Patent date Nov 25, 2025. "FIELD OF THE INVENTION The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes. PGA is one of the most used enzymes globally due to the massive market for beta-lactam antibiotics, with annual consumption estimated in the millions of tons." https://patents.justia.com/patent/12480111
1 · Reply
MHM7700
MHM7700 Dec. 5 at 4:46 PM
35% gains locked in on the $MRK puts. scaling out some here. https://stocktwits.com/MHM7700/message/638215542
0 · Reply
Child_of_Gann786
Child_of_Gann786 Dec. 5 at 4:29 PM
$MRK looks like the move is over
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 5 at 3:49 PM
$MRK $GSK $DVAX
0 · Reply